On August 7, 2024, Sera Prognostics, Inc., a company specializing in pregnancy biomarker information, announced its financial results for the second quarter ended June 30, 2024. The announcement was made through a press release and was accompanied by a conference call and webcast. Sera Prognostics reported a second-quarter revenue of $24,000, a significant decrease from $123,000 in the same period the previous year. The company's total operating expenses decreased by 20% to $9.3 million, down from $11.5 million in Q2 2023. Research and development expenses increased by 19% to $4.4 million, attributed to new product development activities. Selling, general, and administrative expenses saw a 38% reduction to $4.9 million due to efforts to streamline operations and focus commercial strategy. These cost reductions led to a narrower net loss of $8.3 million for the quarter...Show More

On August 7, 2024, Sera Prognostics, Inc., a company specializing in pregnancy biomarker information, announced its financial results for the second quarter ended June 30, 2024. The announcement was made through a press release and was accompanied by a conference call and webcast. Sera Prognostics reported a second-quarter revenue of $24,000, a significant decrease from $123,000 in the same period the previous year. The company's total operating expenses decreased by 20% to $9.3 million, down from $11.5 million in Q2 2023. Research and development expenses increased by 19% to $4.4 million, attributed to new product development activities. Selling, general, and administrative expenses saw a 38% reduction to $4.9 million due to efforts to streamline operations and focus commercial strategy. These cost reductions led to a narrower net loss of $8.3 million for the quarter, improving from a net loss of $10.5 million in the same quarter of the previous year. The company highlighted several business achievements, including the publication of the AVERT PRETERM TRIAL results, the anticipated database lock for the PRIME study, and the conditional approval from New York State for a new blood collection method. Sera Prognostics is actively working on expanding awareness of its PreTRM Test and is implementing multi-channel strategies to educate physicians and patients about its benefits.